Navigation Links
Avandia Attorney Says Study Based on 'Useless Trick Science'
Date:6/5/2009

Today's announcement hurts thousands of Avandia patients, counsel says

HOUSTON, June 5 /PRNewswire/ -- Noted Houston trial lawyer Mark Lanier of The Lanier Law Firm says "useless trick science" is the basis for a new study being unveiled today in New Orleans by drug maker GlaxoSmithKline (NYSE: GSK) about the side effects caused by the company's diabetes medication Avandia, which reportedly has been linked to heart problems in thousands of patients.

Mr. Lanier represents many former Avandia users who suffered heart attacks and other heart problems after taking the drug. The study released today follows six years of research paid for by GlaxoSmithKline to purportedly determine whether Avandia causes heart problems at a higher rate than other diabetes medications. The study results are being presented at the American Diabetes Association's 69th Scientific Sessions, the world's largest diabetes conference.

Among the many problems cited by medical professionals who have reviewed the study's methodology is that not enough participants were included to produce statistically valid results. The study also used Avandia in combination with other drugs rather than determining the effects of taking the drug alone.

"This study is a prime example of getting what you pay for," says Mr. Lanier. "For six years, GlaxoSmithKline has been pouring money into this study to get the results they wanted, and that's exactly what's happening today."

The Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes, or RECORD, study is based on information from diabetes patients who live in Europe. The study results follow a 2007 report in The New England Journal of Medicine, which revealed that Avandia users suffered a 43 percent increase in heart attacks and a 64 percent increase in cardiac deaths.

The U.S. Food and Drug Administration responded by requiring GlaxoSmithKline to include an updated "Black Box" warning on Avandia prescriptions about the potential increased risk of heart attacks. "Black Box" warnings are the most serious warnings required by the FDA, and are used only when a drug presents a significant risk of serious adverse side effects.

Preliminary results from the RECORD study showed no statistically significant difference in heart problems among users of Avandia and other diabetes medications, but Mr. Lanier and others who have reviewed the methodology say the results are unreliable.

"One of the FDA's own researchers said two years ago that he didn't think this study should have been conducted because it couldn't produce scientifically reliable or valid results," says Mr. Lanier. "By using tricks as science and publishing this study, GlaxoSmithKline is disregarding the safety of thousands of diabetes patients in the company's pursuit of the almighty dollar."

With offices in Los Angeles, Palo Alto, Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions in courtrooms across the country. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, intellectual property, business litigation, product liability, toxic exposure and maritime law.

For more information on Avandia, please visit The Lanier Law Firm Web site at www.lanierlawfirm.com. To interview Mr. Lanier, please contact Bruce Vincent at 800-559-4534 or bruce@androvett.com.


'/>"/>
SOURCE The Lanier Law Firm
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Halting Avandia Use Hikes Blood Sugar Levels
2. LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects
3. Avandias Heart Risk Higher Than Others in Its Class
4. Public Citizen Petitions FDA to Ban Diabetes Drug Avandia, According to Avandia Plaintiffs Attorney Group
5. Consumer Group Seeks FDA Ban on Avandia
6. LegalView Re-Launches its Avandia Information Portal with News of the Type 2 Diabetes Drug's Risks and Dangers
7. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
8. Avandia May Slow Atherosclerosis After Bypass Surgery
9. Older Diabetics Using Avandia Face Increased Death Risk
10. Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
11. Diabetes Drug Avandia Could Weaken Bones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... manufacturer, has expanded its executive staff with the addition of industry sales leader, ... role, Slott will develop the national distribution and sales network, direct the efforts ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
Breaking Medicine Technology: